DPWG rules with clinical significance C-F but without actual recommendations
Some rules are classified as C-F by the DPWG although there are no actual recommendations ('none'). For now, these are not categorized as 'important' in the 'modification type' column. The following gene/drug pairs are affected by this:
- CYP2D6 Mirtazapine
- CYP2C9 Phenprocoumon
- CYP3A5 Tacrolimus
- HLA-B44 Ribavirin
- CYP2C9 Glimepiride
- UGT1A1 Irinotecan